Equillium, Inc. (EQ)
NASDAQ: EQ · Real-Time Price · USD
0.9400
+0.0100 (1.08%)
Aug 14, 2025, 2:17 PM - Market open
Equillium Revenue
Equillium had revenue of $30.41M in the twelve months ending March 31, 2025, down -19.76% year-over-year. In the year 2024, Equillium had annual revenue of $41.10M with 13.89% growth.
Revenue (ttm)
$30.41M
Revenue Growth
-19.76%
P/S Ratio
1.08
Revenue / Employee
$868,743
Employees
35
Market Cap
33.58M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 41.10M | 5.01M | 13.89% |
Dec 31, 2023 | 36.08M | 20.33M | 128.97% |
Dec 31, 2022 | 15.76M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
EQ News
- 3 days ago - Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic - Business Wire
- 10 days ago - Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy - Business Wire
- 3 months ago - Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists - Business Wire
- 3 months ago - Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504 - Business Wire
- 4 months ago - Equillium Announces Feedback from the U.S. Food and Drug Administration - Business Wire
- 5 months ago - Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients - Benzinga
- 5 months ago - Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - Business Wire
- 5 months ago - Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights - Business Wire